Novo Nordisk (NOVOb.CO) announced on Monday that it has officially launched its popular obesity treatment, Wegovy, in China—the world’s second-largest pharmaceutical market, where more than 180 million people are estimated to be living with obesity. This launch intensifies competition with Eli Lilly (LLY.N), which received approval